SD-1008
SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway[1].
Product Specifications
CAS Number
[960201-81-4]
UNSPSC
12352005
Target
Apoptosis; JAK; STAT
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sd-1008.html
Purity
99.10
Solubility
10 mM in DMSO
Smiles
O=C([C@H]1[C@H](C2=O)N([C@H](C=C2)[C@H]1C(OC)=O)CC3=CC=CC=C3)OC
Molecular Formula
C18H19NO5
Molecular Weight
329.35
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK2; STAT3
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
STAC (SH3 and Cysteine-rich Domain-containing Protein, Src Homology 3 and Cysteine-rich Domain-containing Protein, FLJ32331) (MaxLight 750)
STAC (SH3 and Cysteine-rich Domain-containing Protein, Src Homology 3 and Cysteine-rich Domain-containing Protein, FLJ32331) (MaxLight 750)
